.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,916,893

« Back to Dashboard

Claims for Patent: 5,916,893

Title: Treatment of a latent infection of herpes virus
Abstract:A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
Inventor(s): Field; Hugh John (Cambridge, GB), Thackray; Alana Maureen (Cambridge, GB), Bacon; Teresa Helen (Epsom, GB), Sutton; David (Phoenixville, PA), Vere Hodge; Richard Anthony (Reigate, GB)
Assignee: SmithKline Beecham p.l.c. (Brentford, GB)
Application Number:08/845,720
Patent Claims: 1. A method for the treatment of a latent infection of herpes viruses in a human in need thereof which method comprises administering to said human an effective amount of a compound of formula (A): ##STR5## or a bioprecurser, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative or either of the foregoing at greater than 18 hours post-infection.

2. A method according to claim 1 wherein the treatment is for latent infection of herpes simplex type 1 infection.

3. A method according to claim 1 wherein the treatment is for latent infection of herpes simplex type 2 infection.

4. A method according to claim 1 wherein the Compound is famciclovir.

5. A method according to claim 4 wherein famciclovir is administered at a dose of 125 mg, 250 mg, 500 mg, 750 mg, or 1 g, once, twice or three times a day.

6. The method according to claim 1 wherein the time of administration is four (4) days or greater post-infection.

7. The method according to claim 1 wherein the length of time for reduction of or reactivation of the latent herpes viruses is from 3 to 14 days.

8. The method according to claim 1 wherein the compound of Formula (A) is penciclovir, or a pharmaceutically acceptable salt thereof.

9. A method for the reduction, or prevention of a herpes virus becoming latent and subsequently reactivating in a human in need thereof, which method comprises administering to said human an effective amount of famciclovir or penciclovir, or a pharmaceutically acceptable salt thereof, at greater than 18 hours post-infection.

10. The method according to claim 9 wherein the latent herpes viral infection is HSV-1.

11. The method according to claim 9 wherein the latent herpes viral infection is HSV-2.

12. The method according to claim 9 wherein famciclovir is administered at a dose of 125 mg, 250 mg, 500 mg, 750 mg, or 1 gram.

13. The method according to claim 12 wherein the dose is administered once, twice or three times a day.

14. The method according to claim 9 wherein the time of administration is four (4) days or greater post-infection.

15. The method according to claim 9 wherein the length of time for reduction of or reactivation of the latent herpes viruses is from 3 to 14 days.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc